ST Life Sciences: Planning to acquire 51% stake in Huize Pharmaceuticals.

On August 11, 2025, Nanhua Biopharmaceutical Co., Ltd. signed an "Intention Agreement for Equity Acquisition" with relevant parties, intending to acquire 51% equity of Hunan Huize Biopharmaceutical Technology Co., Ltd. in cash. Upon completion of the transaction, Huize Medicine will become a wholly-owned subsidiary. Huize Medicine is a CRO company focusing on drug research and clinical evaluation, with strong synergies with the company's business. This acquisition aims to improve the industrial chain. The transaction is not considered a related party transaction, is expected to constitute a major asset reorganization, and does not involve the issuance of shares or changes in control. The intention agreement is preliminary and the specific transaction plan is subject to negotiation, with uncertainty regarding whether the final transaction will be reached. The company will fulfill approval and disclosure obligations in accordance with regulations and reminds investors to be cautious of risks.